- ALS (Lou Gehrig's disease)
- Alzheimer's disease
- Crohn's disease or ulcerative colitis
- Epilepsy or a similar condition that causes "debilitating seizures"
- Multiple sclerosis or persistent and debilitating muscle spasms
- Nausea (must be persistent)
- Pain lasting longer than two weeks that is not adequately managed despite treatment attempts
- PTSD “that is being treated or monitored by a licensed mental health therapist”
- Any terminal illness where life expectancy is less than six months
- Any condition resulting in hospice care
- Any rare condition that effects fewer than 200,000 persons in the United States as defined by Section 526 of the Federal Food, Drug and Cosmetic Act and is not adequately managed despite treatment attempts
**Patients with a qualifying illness between the ages of 18 and 21 must petition the Compassionate Use Board for medical cannabis approval
PATIENT POSSESSION LIMITS
Medical cannabis products are defined explicitly as a “tablet,” “capsule,” “a concentrated oil,” “a liquid suspension,” “a topical preparation,” “a transdermal preparation,” “a sublingual preparation,” “a gelatinous cube or lozenge,” or “a blister pack of unprocessed cannabis flower.” All products must be labeled with a bar code. Patients may obtain up to a 14-day supply of medical cannabis products.
No. Replacement legislation approved by the House and Senate on December 3, 2018 rewrote the Utah Medical Cannabis Act to eliminate any home cultivation option. Proponents of the voter-initiated measure are suing over the changes
Yes, but they are defined as ‘medical pharmacies’ under the replacement legislation. Regulators may issue no more than seven medical pharmacy licenses.
STATE-LICENSED DISPENARIES OPERATIONAL
Yes. Patients may designate no more than two caregivers, who may purchase, transport, or assist the patient in his/her use of medical cannabis in a dosage form